Onyx Names Laura A. Brege Executive Vice President and Chief Business Officer
June 12 2006 - 5:00PM
PR Newswire (US)
EMERYVILLE, Calif., June 12 /PRNewswire-FirstCall/ -- Onyx
Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced the appointment
of Laura Brege as executive vice president and chief business
officer. In this newly created position, Ms. Brege will be
responsible for Finance, Business Development, Legal, Human
Resources, and Investor Relations functions and will report to
Hollings C. Renton, chairman, president, and chief executive
officer of Onyx. "Onyx's growth is fueling the need for additional
executive talent," said Mr. Renton. "Laura's established expertise
in strategic finance, corporate development, and operations will be
critical in building Onyx's oncology business." Most recently Ms.
Brege was a General Partner at Red Rock Management, a venture
capital firm specializing in early stage financing for technology
companies. Prior to Red Rock, she was the Senior Vice President and
Chief Financial Officer at COR Therapeutics, a biotechnology
company that specialized in drug therapies for cardiovascular
disease. While at COR, Ms. Brege was instrumental in helping the
company grow from a research and development start-up to an
operations-based enterprise with a commercialized product. She was
also a member of the management team that negotiated multiple
corporate partnerships, including a worldwide co-promotion
agreement for COR's lead product, as well as corporate partnerships
for earlier programs and products with J&J, Eli Lilly, and
Solvay. Before joining COR, Ms. Brege was Vice President and Chief
Financial Officer at Flextronics, a multi-billion dollar
electronics manufacturer. She was also Vice President and Treasurer
of The Cooper Companies, a Fortune 500 diversified company with
operations worldwide. Ms. Brege earned her undergraduate degree
from Ohio University and has an MBA from the University of Chicago.
About Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. is
engaged in the development of novel cancer therapies that target
the molecular basis of cancer. With its collaborators, the company
is developing small molecule drugs, including Nexavar with Bayer
Pharmaceuticals Corporation. For more information about Onyx's
pipeline and activities, visit the company's web site at:
http://www.onyx-pharm.com/. NOTE: Nexavar(R) (sorafenib) tablets is
a registered trademark of Bayer Pharmaceuticals Corporation. This
press release contains forward-looking statements within the
meaning of the federal securities laws, including statements
regarding the development and the commercial launch of Nexavar(R)
(sorafenib) tablets. These forward-looking statements involve a
number of risks and uncertainties that could cause actual events to
differ from the company's expectations. These risks are addressed
in the company's periodic reports filed with the Securities and
Exchange Commission, including but not limited to its Annual Report
on Form 10-K for the fiscal year ended December 31, 2004, as
amended, and its Quarterly Reports on Form 10-Q. Readers are
cautioned not to place undue reliance on these forward-looking
statements that speak only as of the date of this release. The
company undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date of this release except as required by
law. DATASOURCE: Onyx Pharmaceuticals, Inc. CONTACT: Julie Wood of
Onyx Pharmaceuticals, Inc., +1-510-597-6505 Web site:
http://www.onyx-pharm.com/
Copyright
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jul 2023 to Jul 2024